title: Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy.
abstract: BACKGROUND
  Heart failure occurs predominantly due to coronary artery disease and may be amenable to novel revascularization therapies. This study evaluated the effects of placental growth factor (PlGF), a potent angiogenic agent, in a rat model of ischemic cardiomyopathy.
  
  
  METHODS
  Wistar rats underwent high proximal ligation of the left anterior descending coronary artery and direct injection of PlGF (n = 10) or saline as a control (n = 10) into the myocardium bordering the ischemic area. After 2 weeks, the following parameters were evaluated: ventricular function with an aortic flow probe and a pressure/volume conductance catheter, left ventricular (LV) geometry by histology, and angiogenesis by immunofluorescence.
  
  
  RESULTS
  PlGF animals had increased angiogenesis compared to controls (22.8 +/- 3.5 vs. 12.4 +/- 3.2 endothelial cells/high-powered field, p < 0.03). PlGF animals had less ventricular cavity dilation (LV diameter 8.4 +/- 0.2 vs. 9.2 +/- 0.2 mm, p < 0.03) and increased border zone wall thickness (1.85 +/- 0.1 vs. 1.38 +/- 0.2 mm, p < 0.03). PlGF animals had improved cardiac function as measured by maximum LV pressure (95.7 +/- 4 vs. 73.7 +/- 2 mmHg, p = 0.001), maximum dP/dt (4206 +/- 362 vs. 2978 +/- 236 mmHg/sec, p = 0.007), and ejection fraction (25.7 +/- 2 vs. 18.6 +/- 1%, p = 0.02).
  
  
  CONCLUSIONS
  Intramyocardial delivery of PlGF following a large myocardial infarction enhanced border zone angiogenesis, attenuated adverse ventricular remodeling, and preserved cardiac function. This therapy may be useful as an adjunct or alternative to standard revascularization techniques in patients with ischemic heart failure.
authors.affiliation: Department of Surgery, Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Kolakowski
authors.forename: Mark F
authors.initials: MF
authors.lastname: Berry
authors.forename: Pavan
authors.initials: P
authors.lastname: Atluri
authors.forename: Todd
authors.initials: T
authors.lastname: Grand
authors.forename: Omar
authors.initials: O
authors.lastname: Fisher
authors.forename: M Astrid
authors.initials: MA
authors.lastname: Moise
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Cohen
authors.forename: Vivian
authors.initials: V
authors.lastname: Hsu
authors.forename: Y Joseph
authors.initials: YJ
authors.lastname: Woo
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002302:Cardiac Output; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000503:physiopathology; D007267:Injections; D008297:Male; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D009206:Myocardium; D018919:Neovascularization, Physiologic / Q000187:drug effects; D000072483:Placenta Growth Factor; D011257:Pregnancy Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D016276:Ventricular Function / Q000187:drug effects
chemical_list: D043925:Angiogenesis Inducing Agents; C000608038:Pgf protein, rat; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor